Live view of SEC fundamentals with peer-based benchmarks and implied valuation gaps.
Blend averages both multiples when available.
Current vs implied
If Gilead Sciences, Inc. traded at Vertex Pharmaceuticals Inc / Ma P/E multiple, the stock price would be — (vs $124.91).
Implied from P/E
—
Implied from P/S
$236.15
Bottom-right quadrant is the sweet spot: high growth, low valuation.
| Metric | GILD | Delta vs VRTX | VRTX | Context |
|---|---|---|---|---|
Revenue growth (LTM) | 6.0% | 48.2% lower | 11.7% | Growth lag |
Gross margin | 78.3% | 9.1% lower | 86.1% | Pricing power |
EBITDA margin | 18.7% | 278.8% higher | 4.9% | Operating leverage |
EV/Revenue | 6.01x | 40.0% lower | 10.02x | Multiple discount |
P/E | 319.11x | Not comparable | -211.02x | Not comparable |
Net debt / EBITDA | 4.1 | 196.6% higher | -4.2 | Lower leverage |
Quality signals that explain why a cheap stock might stay cheap.
Partial coverage: 8/9 checks
Partial coverage: 7/9 checks
GILD CIK: 882095
VRTX CIK: 875320
